The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage epidermal growth factor receptor (EGFR)-mutation-positive (M+) non-small cell lung cancer (NSCLC). The statement discusses pathologic, diagnostic, and therapeutic considerations and provides recommendations for clinical guidance and research priorities.1
This report, published in the Journal of Thoracic Oncology, outlines optimal choice of EGFR tyrosine kinase inhibitors (TKIs), role of re-biopsies, management of brain metastasis, and use of circulating free DNA for molecular studies.
Patients with EGFR M+ NSCLC usually experience high response rates and improved outcomes. This subset of patients with NSCLC has particularly benefitted from EGFR TKIs. The IASLC responded to these rapid changes in treatment for this subgroup of patients to review emerging data and provide recommendations for contemporary management of the disease.
“Scientific knowledge about EGFR mutation has advanced dramatically since its discovery in 2004, and these advances have made a direct impact on the clinical management of patients with NSCLC. Noting the importance of understanding EGFR, experts from the IASLC published a report in 2013,” said Tony Mok, MD, professor in the Department of Clinical Oncology at the Chinese University of Hong Kong in Prince of Wales Hospital in Hong Kong, and corresponding author of the report.
“However, given the rapidly evolving clinical paradigms, the IASLC again gathered its experts. I have little doubt that the current review offers practitioners cutting edge information in 2016.”
The IASLC report envisions quickly advancing treatments for patients with EGFR M+ NSCLC, especially as new combinations of treatments that incorporate immunotherapy and biomarker testing are increasingly used. These advances have resulted in longer survival, often with sequential treatment options.
“This consensus statement represents a distillation of over a decade of bench-to-bedside research, during which time the clinical community has seen the transformation of metastatic NSCLC into a potentially manageable chronic condition,” said Fred R. Hirsch, MD, PhD, senior author of the article and professor of medicine and pathology at the University of Colorado Cancer Center and School of Medicine, Aurora, Colorado, and CEO of the IASLC.